The Global Angioplasty Balloons Market is projected to reach $2.69 billion by 2028, from a value of $1.96 billion in 2022, by registering a CAGR of 5.4% during the forecast period. Increasing burden of cardiovascular diseases, increased occurrence of lifestyle-related disorders, rise in clinical trial candidates, high investment in research and development, increasing geriatric populations, and increasing preference for minimally invasive procedures are the major factors propelling the growth of the market. However, high costs and complications associated with angioplasty procedures are hampering market growth. Moreover, ever-rising technological advancement and innovation of new instruments, rising launch of new innovative products, and surging prevalence of coronary and periphery artery diseases in the underdeveloped economies are creating ample opportunities across the globe.
Recent Developments
In November 2020, Infinity Angioplasty Balloon Co. announced its innovative angioplasty balloon platform called Infinity Angioplasty Balloon Catheter, and successfully completed a First-in-Human clinical trial. The device received FDA clearance for PTA treatment of peripheral arterial disease, in peripheral vasculature including iliac, femoral, popliteal, infra-popliteal arteries, and for the treatment of AV dialysis fistulae in June 2020.
In September 2020, Medgyn has completed the acquisition of Thomas Medical in order enhance its portfolio in single-use medical devices and accessories. Thomas Medical has a longstanding reputation that has spanned decades as a reliable brand for single-use medical devices and accessories. This acquisition underscores MedGyn’s strong commitment to both patients and healthcare professionals by continuing to provide trusted products and services in women’s healthcare.
In October 2019, Koninklijke Philips N.V. had brought out two new balloons to its portfolio of Stellarex 0.035 low-dose drug-coated balloon (DCB). Both the new balloons that are 200mm and 150mm Stellarex 0.035 had received clearance and approval from the U.S. Food and Drug Administration (FDA) for the treatment of peripheral artery disease (PAD) patients.
In June 2019, Terumo Corp. had done the strategic partnership with Orchestra BioMed, Inc., for the purpose of getting commercialization rights to Virtue Sirolimus-Eluting Balloon (SEB) for percutaneous coronary that will support in meeting the unmet need in procedure-based medicine.
Competitive Landscape
Abbott Laboratories, Medtronic Plc, Becton, Dickinson and Company, Cardinal Health, Boston Scientific Corporation, INFINITY Angioplasty Balloon, Cook Medical, Inc., Spectranetics Corp., Endocor GmbH, Johnson & Johnson, AngioDynamics, Koninklijke Philips N.V., Terumo Medical Corporation, Biotronik SE & Co. KG, Braun Melsungen AG, Merit Medical Systems, Inc., Oscor Inc., Teleflex Incororated, Medgyn, and Nipro Medical Corporation are some of the major players in the global Angioplasty Balloons market.
